המידע באדיבות מדיקונטקסט
Last Updated: 2001-07-16 13:35:02 EDT (Reuters Health)
WESTPORT, CT (Reuters Health) – The macrolide antibiotic telithromycin achieves concentrations in the lung that should be able to destroy several bacteria commonly associated with community-acquired pneumonia (CAP) and chronic obstructive pulmonary disease (COPD).
Dr. O. A. Khair, from City Hospital NHS Trust, Birmingham, UK, and colleagues measured lung and plasma concentrations of telithromycin in 20 subjects who received an 800-mg oral dose of the drug, once daily, for 5 days. The concentrations were determined 2, 12, or 24 hours after the final dose.
Plasma, bronchial mucosa (BM), and epithelial lining fluid (ELF) concentrations of telithromycin decreased as the testing interval increased. However, even at 24 hours, the BM and ELF concentrations exceeded the mean minimum inhibitory concentrations of Streptococcus pneumoniae, Moraxella catarrhalis, and Mycoplasma pneumoniae, the authors note.
Alveolar macrophage (AM) concentrations of the drug were 69.32 mg/L at 2 hours, 318.1 mg/L at 12 hours, and 161.57 mg/L at 24 hours. "High AM concentrations suggest that telithromycin may have good activity against intracellular pathogens Chlamydia pneumoniae and Legionella pneumophila," the researchers point out in the June issue of the Journal of Antimicrobial Chemotherapy.
Dr. Khair's team concludes that "these data suggest that telithromycin may be effective for the treatment of respiratory infections and is worthy of further investigation."
J Antimicrob Chemother 2001;47:837-840.
-Westport Newsroom 203 319 2700